STOCK TITAN

Evaxion Biotech A/S American Depositary Share - EVAX STOCK NEWS

Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.

Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.

Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.

The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.

Recent news highlights key company activities, such as:

  • A replay of the R&D Day presentations is available on the company's website.
  • Information about the EVX-01 Phase 2 clinical trial.
  • The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.

To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.

Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) has entered into a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB. This partnership aims to develop a novel cytomegalovirus (CMV) vaccine candidate utilizing Evaxion's AI platform, RAVEN, for antigen design. Costs for the collaboration will be split evenly until 2025. A potential future agreement could provide Evaxion with milestone payments and royalties based on CMV asset sublicensing. CMV represents a significant unmet medical need, especially for immunocompromised individuals and congenitally infected infants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced promising interim data from its Phase 1/2a clinical trial for its DNA-based cancer immunotherapy, EVX-02. The treatment, aimed at melanoma, showed a well-tolerated safety profile with only mild adverse events. All patients exhibited robust CD4+ and CD8+ T-cell responses, highlighting the efficacy of their AI-driven technology for personalized cancer treatment. A full report of the trial results is expected in Q2 2023, as the company looks forward to advancing their next-generation DNA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
-
Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) announced its Q3 2022 financial results, highlighting the enrollment of the first patient in a Phase 2b trial for its cancer immunotherapy EVX-01. The company reported cash and equivalents of $17.9 million, sufficient to support operations into mid-2023. The R&D expenses decreased to $4.1 million compared to $4.4 million in Q3 2021, while general and administrative expenses rose to $2.0 million. Despite a net loss of $5.7 million for the quarter, Evaxion is focused on its oncology assets and pursuing strategic partnerships. Guidance remains optimistic for ongoing projects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
News
Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) announced a strategic shift to focus on its leading oncology assets, EVX-01 and EVX-02/03, aiming for clinical proof of concept before potential out-licensing. New CEO Per Norlén emphasized the need for concentration on personalized cancer immunotherapies while preclinical infectious disease programs will seek partnerships. The Phase IIb trial for EVX-01 is underway, with mid-2023 data expected for EVX-02. Promising pre-clinical results for EVX-03 suggest superior efficacy, with plans for regulatory submission following EVX-02 outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
none
-
Rhea-AI Summary

Abalos Therapeutics has appointed Thomas Bogenrieder, MD, PhD, as its new Chief Medical Officer. Dr. Bogenrieder brings over 17 years of international experience in clinical development, particularly in cancer immunotherapies. His expertise will bolster Abalos' efforts in clinical and regulatory strategies for its arenavirus-based product candidates aimed at treating solid tumors. Previously, he served as Chief Medical Officer at Evaxion Biotech and has held senior roles at Boehringer Ingelheim and GlaxoSmithKline. This leadership change is expected to enhance Abalos' innovation in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
management
-
News
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announces the appointment of Per Norlén as its new CEO, effective October 3, 2022. With over 20 years in biotech, Norlén aims to propel Evaxion's capabilities in developing AI-driven immunotherapies for cancer. He expresses confidence in the company’s potential, especially following promising phase 1 trial results in melanoma. Chairman Marianne Soegaard highlights Norlén's leadership as key to advancing the company's innovative clinical and preclinical results. Evaxion is focused on tailored therapies for cancer and other critical diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
management
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announced the enrollment of its first patient in a global Phase 2b clinical trial for EVX-01, a personalized cancer therapy targeting melanoma. This trial, conducted in collaboration with Merck, aims to evaluate the safety and efficacy of EVX-01 alongside KEYTRUDA®. Earlier Phase 1/2a data showed that 67% of patients benefited from the combination treatment, with 22% achieving complete recovery. Interim topline data is anticipated in the second half of 2023, highlighting potential advancements in melanoma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.63%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) has collaborated with UMass Chan Medical School to receive a grant from the U.S. NIH for developing a gonorrhea vaccine candidate. This initiative, part of Evaxion's EVX-B2 project utilizing their AI platform EDEN, aims to address a significant unmet medical need as gonorrhea is a critical antibiotic resistance threat. The vaccine has shown promise in preclinical studies. With the NIH grant, Evaxion intends to advance this innovative vaccine solution to combat gonorrhea infections, which currently lack effective prevention methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
-
Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX) reported significant advancements in its immunotherapy programs during Q2 2022, including the expansion into non-small cell lung cancer and production of personalized cancer treatments for melanoma. The company identified gonorrhea as its second bacterial product target. Despite a net loss of $4.8 million and cash reserves of $25.3 million, Evaxion anticipates these funds will support development efforts for the next year. Plans to initiate a Phase 2b trial in partnership with Merck's KEYTRUDA® are also highlighted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Rhea-AI Summary

Evaxion Biotech A/S (NASDAQ: EVAX) announces significant executive changes, with Lars Staal Wegner resigning as CEO but staying on as an advisor. Per Norlén, M.D., Ph.D., with over 20 years in clinical drug development, has been appointed as the new CEO. Norlén's experience in oncology and leadership at biopharmaceutical companies is expected to strengthen Evaxion's management as they pursue new partnerships and consolidate future projects. Chair Marianne Soegaard expressed confidence in Norlén's ability to enhance the company's growth and benefit stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
management

FAQ

What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?

The current stock price of Evaxion Biotech A/S American Depositary Share (EVAX) is $0.9077 as of December 23, 2024.

What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?

The market cap of Evaxion Biotech A/S American Depositary Share (EVAX) is approximately 5.3M.

What does Evaxion Biotech A/S specialize in?

Evaxion Biotech A/S specializes in developing novel vaccines and therapies using artificial intelligence to solve significant health challenges.

What are the main AI platforms used by Evaxion Biotech?

Evaxion Biotech uses the PIONEER, EDEN, RAVEN, and ObsERV AI platforms for drug discovery and development.

What are Evaxion's leading product candidates?

Evaxion's leading product candidates include EVX-01 and EVX-02 for cancer treatment and EVX-03 for non-small-cell lung cancer.

What recent developments have taken place at Evaxion Biotech?

Recent developments include a replay of the R&D Day presentations, information about the EVX-01 Phase 2 clinical trial, and a resolution of a Nasdaq equity deficiency issue.

When was Evaxion Biotech A/S founded?

Evaxion Biotech A/S was founded in 2008.

How does the EDEN platform contribute to Evaxion's research?

The EDEN platform aids in the rapid discovery of novel antigens that elicit cross-protective immune responses against bacterial pathogens.

What is PIONEER platform's role in Evaxion's operations?

The PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses, particularly in cancer treatments.

What kind of financial challenges has Evaxion recently addressed?

Evaxion addressed a Nasdaq equity deficiency issue related to the IFRS accounting treatment of investor warrants by converting the exercise price from USD to DKK.

Where can I find more information about Evaxion's recent activities?

More information about Evaxion's recent activities can be found on their official website at www.evaxion-biotech.ai.

What is the mission of Evaxion Biotech A/S?

The mission of Evaxion Biotech A/S is to tackle significant global health challenges using artificial intelligence to develop novel vaccines and immunotherapies.

Evaxion Biotech A/S American Depositary Share

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

5.28M
4.17M
25.25%
9.9%
0.61%
Biotechnology
Healthcare
Link
United States of America
Horsholm